|
covid-19 |
86 |
|
epidemiology |
52 |
|
chinese |
48 |
|
children |
43 |
|
sars-cov-2 |
43 |
|
mortality |
41 |
|
covid-19 vaccine |
39 |
|
atrial fibrillation |
38 |
|
cancer |
32 |
|
stroke |
32 |
|
bnt162b2 |
29 |
|
coronavac |
29 |
|
vaccine safety |
29 |
|
covid-19 vaccines |
27 |
|
diabetes |
27 |
|
heart failure |
25 |
|
hong kong |
25 |
|
school closure |
21 |
|
cardiovascular disease |
20 |
|
public health |
20 |
|
dementia |
19 |
|
vitamin d |
19 |
|
inactivated vaccine |
18 |
|
myocardial infarction |
18 |
|
osteoporosis |
18 |
|
self-controlled case series |
18 |
|
type 2 diabetes mellitus |
18 |
|
sars |
17 |
|
child psychosocial problems |
16 |
|
coronavirus |
16 |
|
healthcare workers |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
meta-analysis |
16 |
|
perceived stress |
16 |
|
pharmacoepidemiology |
16 |
|
psychological wellbeing |
16 |
|
systematic review |
16 |
|
adverse events |
15 |
|
diabetes mellitus |
15 |
|
ischemic stroke |
15 |
|
vaccine effectiveness |
15 |
|
adult |
14 |
|
cohort studies |
14 |
|
cohort study |
14 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
infants |
14 |
|
screen time |
14 |
|
aspirin |
13 |
|
cytokines |
13 |
|
immunoglobulin |
13 |
|
lymphocyte subsets |
13 |
|
major adverse cardiovascular events |
13 |
|
sex difference |
13 |
|
bacteria |
12 |
|
colorectal cancer |
12 |
|
depression |
12 |
|
false positive |
12 |
|
innate immunity |
12 |
|
kawasaki disease |
12 |
|
paediatrics |
12 |
|
serology |
12 |
|
tuberculosis |
12 |
|
warfarin |
12 |
|
adolescent |
11 |
|
allergy |
11 |
|
hypertension |
11 |
|
mendelian randomization |
11 |
|
metformin |
11 |
|
omicron |
11 |
|
pregnancy |
11 |
|
statistics & research methods |
11 |
|
time in therapeutic range |
11 |
|
adolescence |
10 |
|
all-cause pneumonia |
10 |
|
asia |
10 |
|
asparaginase |
10 |
|
autoimmune disorders |
10 |
|
delirium |
10 |
|
gastrointestinal haemorrhage |
10 |
|
herd immunity |
10 |
|
human leukocyte antigens |
10 |
|
hypersensitivity |
10 |
|
incident cvd |
10 |
|
interrupted time series analysis |
10 |
|
long covid |
10 |
|
pasc |
10 |
|
pharmacy |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
prescribing |
10 |
|
safety |
10 |
|
adverse events of special interest (aesi) |
9 |
|
age-stratified |
9 |
|
aged |
9 |
|
antidepressants |
9 |
|
blood pressure |
9 |
|
bone mineral density |
9 |
|
cardiovascular complications |
9 |
|
down syndrome |
9 |
|
drug utilization |
9 |
|
health sciences |
9 |
|
infection |
9 |
|
medicine |
9 |
|
microvascular complications |
9 |
|
molnupiravir |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
nursing |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
rheumatoid arthritis |
9 |
|
secondary prevention |
9 |
|
serum 25-hydroxyvitamin d |
9 |
|
statins |
9 |
|
travel history |
9 |
|
undergraduate students |
9 |
|
vaccine |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
abdominal pain |
8 |
|
adverse events of special interest |
8 |
|
antimicrobial resistance |
8 |
|
antiresorptives |
8 |
|
cardiovascular diseases |
8 |
|
dabigatran |
8 |
|
diarrhoea |
8 |
|
drug regulatory |
8 |
|
family hardship |
8 |
|
health disparity |
8 |
|
health equity |
8 |
|
hospitalisation |
8 |
|
latent class analysis |
8 |
|
meningitis |
8 |
|
mrna vaccine |
8 |
|
myocarditis |
8 |
|
neonates |
8 |
|
odds ratio |
8 |
|
orphan drug policy |
8 |
|
paediatric gastroenterology |
8 |
|
pediatric population |
8 |
|
pericarditis |
8 |
|
preschooler |
8 |
|
rare diseases |
8 |
|
risk factor |
8 |
|
treatment access |
8 |
|
adenocarcinoma |
7 |
|
alcoholism |
7 |
|
anxiety disorder |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
carriage |
7 |
|
colonoscopy |
7 |
|
coronary artery disease |
7 |
|
covid-19 pandemic |
7 |
|
dialysis patients |
7 |
|
early childhood exposure |
7 |
|
early-life activities |
7 |
|
elderly |
7 |
|
elderly care |
7 |
|
electronic health records |
7 |
|
family financial pressure |
7 |
|
glycated haemoglobin |
7 |
|
hemoglobin a1c |
7 |
|
indirect effect |
7 |
|
mental disorders |
7 |
|
nested case-control study |
7 |
|
peritoneal dialysis |
7 |
|
physical activity |
7 |
|
primary care |
7 |
|
psychosocial development |
7 |
|
renal replacement therapy |
7 |
|
school closures |
7 |
|
school-aged children |
7 |
|
sleep |
7 |
|
telomere |
7 |
|
therapeutics |
7 |
|
vaccination |
7 |
|
visit‐to‐visit variability |
7 |
|
adverse drug reactions |
6 |
|
all-cause mortality |
6 |
|
anaphylaxis |
6 |
|
angiotensin receptor blockers |
6 |
|
angiotensinconverting enzyme inhibitors |
6 |
|
anti-coagulant |
6 |
|
antimicrobial stewardship |
6 |
|
asthma |
6 |
|
bmi |
6 |
|
bone loss |
6 |
|
bone metabolism |
6 |
|
bone mineral testing |
6 |
|
burden of disease |
6 |
|
calcium |
6 |
|
cardiovascular mortality |
6 |
|
challenge |
6 |
|
chronic kidney disease |
6 |
|
covid-19 incidence |
6 |
|
cox regression |
6 |
|
cvd |
6 |
|
data repository |
6 |
|
dipeptidyl peptidase-4 inhibitors |
6 |
|
disease and disorders of/related to bone |
6 |
|
doac |
6 |
|
drug |
6 |
|
drug safety |
6 |
|
epidemiological studies |
6 |
|
gastroenterology |
6 |
|
gastrointestinal bleeding |
6 |
|
gastrointestinal tumours |
6 |
|
general population studies |
6 |
|
hdl‐c |
6 |
|
healthcare resource |
6 |
|
intellectual disability |
6 |
|
intensive care unit |
6 |
|
intubation |
6 |
|
ldl‐c |
6 |
|
lipids variability |
6 |
|
meta-data |
6 |
|
mineral metabolism |
6 |
|
neurogen |
6 |
|
neuroleptic agent |
6 |
|
neurological and mental health global epidemiology network |
6 |
|
non-steroidal anti-inflammatory drugs |
6 |
|
nsaids |
6 |
|
obesity |
6 |
|
pneumonia admission |
6 |
|
population aging |
6 |
|
population-based study |
6 |
|
preventive medicine |
6 |
|
psychological symptoms |
6 |
|
respiratory tract infections |
6 |
|
retrospective cohort |
6 |
|
rhinitis |
6 |
|
rickets |
6 |
|
snoring |
6 |
|
sodium-glucose co-transporter |
6 |
|
sodium-glucose cotransporter-2 inhibitors |
6 |
|
stomach cancer |
6 |
|
suicide |
6 |
|
telomere length |
6 |
|
variability |
6 |
|
adhd |
5 |
|
adulthood |
5 |
|
adverse drug event |
5 |
|
adverse drug reaction |
5 |
|
agranulocytosis |
5 |
|
angiotensin-converting enzyme inhibitors |
5 |
|
antibiotics |
5 |
|
anticoagulant |
5 |
|
anticoagulation |
5 |
|
antiplatelets |
5 |
|
avascular necrosis |
5 |
|
bdmards |
5 |
|
bleeding |
5 |
|
bone turnover markers |
5 |
|
cancer incidence |
5 |
|
cancer risk |
5 |
|
cardiovascular disease risk |
5 |
|
cardiovascular safety of biologics |
5 |
|
cdars |
5 |
|
chemoprevention |
5 |
|
child |
5 |
|
child maltreatment |
5 |
|
chinese medicine |
5 |
|
ciclosporin |
5 |
|
clinical outcomes |
5 |
|
clopidogrel |
5 |
|
cohort analysis |
5 |
|
colon cancer |
5 |
|
colonic neoplasms |
5 |
|
comorbidity |
5 |
|
cord blood |
5 |
|
covid |
5 |
|
cytochrome 3a4 |
5 |
|
cytokine |
5 |
|
direct oral anticoagulants |
5 |
|
donepezil |
5 |
|
drug escalation |
5 |
|
effectiveness |
5 |
|
electronic frailty index |
5 |
|
enalapril |
5 |
|
family support |
5 |
|
follow-up |
5 |
|
fracture |
5 |
|
genetics |
5 |
|
global healthsales |
5 |
|
glucocorticoids |
5 |
|
herb-drug interaction |
5 |
|
herbal teas |
5 |
|
hospitals |
5 |
|
inactivated vaccines |
5 |
|
income level |
5 |
|
inflammation |
5 |
|
inflammatory bowel disease |
5 |
|
insulin |
5 |
|
international normalized ratio |
5 |
|
interrupted time series |
5 |
|
interval cancer |
5 |
|
intracranial hemorrhage |
5 |
|
jak inhibitors |
5 |
|
lipid-modifying agents |
5 |
|
low-density lipoprotein cholesterol |
5 |
|
medication safety |
5 |
|
memantine |
5 |
|
mother-offspring dyad |
5 |
|
non-vitamin k antagonist oral anticoagulants |
5 |
|
non-vitamin k oral anticoagulants |
5 |
|
non–vitamin k antagonist oral anticoagulants |
5 |
|
nsaid |
5 |
|
older adults |
5 |
|
oral anticoagulant |
5 |
|
orphan drug designation |
5 |
|
p2y12 inhibitors |
5 |
|
percutaneous coronary intervention |
5 |
|
pharmacoepidemiolgy |
5 |
|
physical fitness |
5 |
|
postmarketing surveillance |
5 |
|
post‐colonoscopy colorectal cancer |
5 |
|
propensity score |
5 |
|
pulmonary hypertension |
5 |
|
random survival forest (rsf) |
5 |
|
readmission |
5 |
|
real-world observational study |
5 |
|
real‐life |
5 |
|
renal complications |
5 |
|
renin |
5 |
|
research design |
5 |
|
risk factors |
5 |
|
risk stratification |
5 |
|
risk–benefit trade-off |
5 |
|
rivaroxaban |
5 |
|
rivastigmine |
5 |
|
sacubitril/valsartan |
5 |
|
sales trends |
5 |
|
self-harm |
5 |
|
sirolimus |
5 |
|
stress |
5 |
|
supplementation |
5 |
|
telemonitoring |
5 |
|
thiazolidinediones |
5 |
|
traditional chinese medicine |
5 |
|
transient ischaemic attack |
5 |
|
treatment outcome |
5 |
|
type 2 diabetes |
5 |
|
underweight |
5 |
|
young age of onset |
5 |
|
accident and emergency department attendances |
4 |
|
adverse outcome |
4 |
|
ageaged |
4 |
|
alzheimer’s disease |
4 |
|
ampk |
4 |
|
anti-diabetic drug |
4 |
|
anticoagulant agent |
4 |
|
antimicrobials |
4 |
|
antiplatelet |
4 |
|
antiplatelet drugs |
4 |
|
anxiety |
4 |
|
arrhythmias |
4 |
|
arrhythmogenic right ventricular cardiomyopathy/dysplasia |
4 |
|
asians |
4 |
|
atomoxetine |
4 |
|
attention deficit hyperactivity disorder |
4 |
|
bia |
4 |
|
biostatistics |
4 |
|
brugada syndrome |
4 |
|
cancer epidemiology |
4 |
|
cardiac |
4 |
|
causal associations |
4 |
|
child development |
4 |
|
ct |
4 |
|
database |
4 |
|
depolarization |
4 |
|
diabetes complication |
4 |
|
dosing |
4 |
|
drug use |
4 |
|
dxa |
4 |
|
ecg |
4 |
|
electronic prescribing |
4 |
|
female |
4 |
|
gastric adenocarcinoma |
4 |
|
gestation |
4 |
|
helicobacter pylori |
4 |
|
helicobacterpylori |
4 |
|
hospital admissions |
4 |
|
humans |
4 |
|
initiation |
4 |
|
insulin therapy |
4 |
|
latency interval |
4 |
|
latent variable |
4 |
|
ldl-c |
4 |
|
lean mass |
4 |
|
medication errors |
4 |
|
mendelian randomisation |
4 |
|
methylphenidate |
4 |
|
multimorbidity |
4 |
|
nafld |
4 |
|
nafld liver fat score |
4 |
|
nonnegative matrix factorization |
4 |
|
offspring |
4 |
|
peptic ulcer |
4 |
|
pharmacy and pharmacology |
4 |
|
prevalence |
4 |
|
prevention |
4 |
|
primary prevention |
4 |
|
prolactin |
4 |
|
psychotic disorders |
4 |
|
questionnaires |
4 |
|
repolarization |
4 |
|
retinal detachment |
4 |
|
sarcopenia |
4 |
|
seizure |
4 |
|
self-controlled case series studies |
4 |
|
sglt2 inhibitor |
4 |
|
statin |
4 |
|
stomach |
4 |
|
substance use disorders |
4 |
|
sudden death |
4 |
|
tachycardia |
4 |
|
taiwan |
4 |
|
thyroid |
4 |
|
tofacitinib |
4 |
|
toxic epidermal necrolysis (ten) |
4 |
|
ventricular |
4 |
|
ventricular arrhythmias |
4 |
|
ventricular fibrillation |
4 |
|
ventricular tachycardia |
4 |
|
abbreviations |
3 |
|
accuracy |
3 |
|
active surveillance |
3 |
|
adolescents |
3 |
|
adults |
3 |
|
aggression |
3 |
|
anticoagulation therapy |
3 |
|
antidepressant |
3 |
|
antiepileptics |
3 |
|
antipsychotic |
3 |
|
antipsychotics |
3 |
|
antirheumatic agents |
3 |
|
arthritis |
3 |
|
attention deficit disorder |
3 |
|
attention-deficit/hyperactivity disorder |
3 |
|
buccal |
3 |
|
calcium & bone |
3 |
|
cardiovascular |
3 |
|
chemicals and cas registry numbers |
3 |
|
child, preschool |
3 |
|
china |
3 |
|
cholesterol |
3 |
|
clinical pharmacology |
3 |
|
cost-effectiveness analysis |
3 |
|
deferasirox |
3 |
|
deferiprone |
3 |
|
deferoxamine |
3 |
|
diabetes & endocrinology |
3 |
|
drug costs |
3 |
|
drug side effect |
3 |
|
emergency medicine |
3 |
|
esophageal cancer |
3 |
|
esophagectomy |
3 |
|
experiences |
3 |
|
genetic test |
3 |
|
genetic variants |
3 |
|
great britain |
3 |
|
h2ra |
3 |
|
haemoglobinopathies |
3 |
|
health expenditures |
3 |
|
health information technology |
3 |
|
healthcare cost |
3 |
|
heart disease |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors |
3 |
|
icd-9 |
3 |
|
impairment |
3 |
|
individualized medicine |
3 |
|
janus kinases |
3 |
|
lithium |
3 |
|
long qt syndrome |
3 |
|
lorcaserin |
3 |
|
machine learning |
3 |
|
markov model |
3 |
|
medical sciences |
3 |
|
medication regimen complexity |
3 |
|
meta‐analysis |
3 |
|
methodology |
3 |
|
micronutrients |
3 |
|
mucoadhesive |
3 |
|
mucosal delivery |
3 |
|
neoadjuvant chemoradiotherapy |
3 |
|
neutrophil-to-lymphocyte ratio |
3 |
|
observational study |
3 |
|
parkinson's disease |
3 |
|
pediatric |
3 |
|
pharmaceutical care |
3 |
|
pharmaceutical preparations |
3 |
|
pharmacogenomics |
3 |
|
pharmacotherapy |
3 |
|
positive predictive value |
3 |
|
ppi |
3 |
|
prescribing trend |
3 |
|
psychopharmacology |
3 |
|
psychotropic drugs |
3 |
|
qualitative |
3 |
|
questionnaire |
3 |
|
questionnaire survey |
3 |
|
random survival forest |
3 |
|
retina |
3 |
|
retrospective studies |
3 |
|
rheumatoid |
3 |
|
stroke prophylaxis |
3 |
|
sublingual |
3 |
|
suicide attempt |
3 |
|
survey |
3 |
|
treatment |
3 |
|
violence |
3 |
|
weight loss |
3 |
|
within-individual comparison |
3 |
|
adverse event |
2 |
|
ages |
2 |
|
aging |
2 |
|
air pollution |
2 |
|
allopurinol |
2 |
|
article |
2 |
|
attention deficit disorder with hyperactivity |
2 |
|
autism spectrum disorder |
2 |
|
barriers |
2 |
|
beers criteria |
2 |
|
benzodiazepine |
2 |
|
biologic |
2 |
|
brain hemorrhage |
2 |
|
cardiovascular risk |
2 |
|
case study |
2 |
|
clinical trial |
2 |
|
clostridium difficile |
2 |
|
cognitive impairment |
2 |
|
community care |
2 |
|
controlled study |
2 |
|
data collection |
2 |
|
dose-response relationship, drug |
2 |
|
drug dosage calculations |
2 |
|
drug efficacy |
2 |
|
drug prescriptions - standards |
2 |
|
drug related hospital admission |
2 |
|
drug therapy, combination |
2 |
|
end-of-life drug |
2 |
|
england - epidemiology |
2 |
|
extemporaneous |
2 |
|
fc-fusion protein |
2 |
|
febuxostat |
2 |
|
formulation |
2 |
|
fracture prevention |
2 |
|
gastrointestinal ulcers (gius) |
2 |
|
general practitioner |
2 |
|
gout |
2 |
|
gross domestic product |
2 |
|
head and neck cancer |
2 |
|
health care surveys |
2 |
|
histamine-2-receptor antagonists (h2ras) |
2 |
|
homes for the aged |
2 |
|
hospitalization - statistics & numerical data |
2 |
|
human |
2 |
|
inappropriate prescribing |
2 |
|
incidence |
2 |
|
infant |
2 |
|
infant, newborn |
2 |
|
intranasal |
2 |
|
italy |
2 |
|
legislation |
2 |
|
london |
2 |
|
lung cancer |
2 |
|
mab |
2 |
|
male |
2 |
|
medication errors - prevention & control |
2 |
|
menopause |
2 |
|
middle aged |
2 |
|
multinational study |
2 |
|
mutagenic effects |
2 |
|
netherlands |
2 |
|
non-steroidal anti-infl ammatory drugs (nsaids) |
2 |
|
nursing homes |
2 |
|
off-label use |
2 |
|
opioid |
2 |
|
oral anticoagulants |
2 |
|
paediatric |
2 |
|
palliative care |
2 |
|
patient compliance |
2 |
|
pharmaceutical services |
2 |
|
physician's practice patterns - statistics & numerical data |
2 |
|
polypharmacy |
2 |
|
prospective studies |
2 |
|
proton pump inhibitors |
2 |
|
psychopharmacology; epidemiology |
2 |
|
quality of life |
2 |
|
randomized controlled trial |
2 |
|
review |
2 |
|
sequence symmetry analysis |
2 |
|
serotonin reuptake inhibitor |
2 |
|
ssri |
2 |
|
stability |
2 |
|
stopp/start criteria |
2 |
|
strokebleeding |
2 |
|
thalassaemia |
2 |
|
united kingdom |
2 |
|
vascular dementia |
2 |
|
vigabatrin |
2 |
|
xanthine oxidase inhibitor |
2 |
|
abnormalities, drug-induced - prevention & control |
1 |
|
acute pain |
1 |
|
admission rate |
1 |
|
adolescent development |
1 |
|
adolescent health |
1 |
|
adolsecents |
1 |
|
adrenergic beta-agonists - therapeutic use |
1 |
|
adrenergic uptake inhibitors - administration & dosage - adverse effects |
1 |
|
adrenergic uptake inhibitors - administration & dosage - pharmacology |
1 |
|
adrenergic uptake inhibitors - adverse effects - therapeutic use |
1 |
|
adrs |
1 |
|
adverse |
1 |
|
adverse drug reaction reporting systems |
1 |
|
adverse drug reaction reporting systems - organization & administration |
1 |
|
adverse drug reaction reporting systems - statistics & numerical data |
1 |
|
adverse neuropsychiatric events |
1 |
|
adverse reaction |
1 |
|
adverse-drug-reactions |
1 |
|
age |
1 |
|
age bands |
1 |
|
age distribution |
1 |
|
age factors |
1 |
|
age of conversion |
1 |
|
aged, 80 and over |
1 |
|
agitation |
1 |
|
akathisia |
1 |
|
algorithm |
1 |
|
amoxicillin |
1 |
|
analgesia |
1 |
|
analgesic |
1 |
|
analgesics - therapeutic use |
1 |
|
analgesics, opioid - therapeutic use |
1 |
|
anti-allergic agents - therapeutic use |
1 |
|
anti-asthmatic agents - adverse effects - therapeutic use |
1 |
|
anti-bacterial agents |
1 |
|
anti-bacterial agents - administration & dosage |
1 |
|
anti-bacterial agents - administration and dosage |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
anti-epileptic drugs |
1 |
|
anti-inflammatory agents |
1 |
|
anti-inflammatory agents, non-steroidal - therapeutic use |
1 |
|
anti-obesity agents - adverse effects - therapeutic use |
1 |
|
anti-obesity agents - therapeutic use |
1 |
|
anti-obesity drug |
1 |
|
antibiotic |
1 |
|
antibiotic dosing |
1 |
|
anticonvulsant |
1 |
|
anticonvulsants - administration & dosage - adverse effects |
1 |
|
anticonvulsants - adverse effects |
1 |
|
anticonvulsants - adverse effects - therapeutic use |
1 |
|
anticonvulsants - therapeutic use |
1 |
|
anticonvulsants/antiepileptic drugs |
1 |
|
antidepressive agents - therapeutic use |
1 |
|
antidiabetic drugs |
1 |
|
antidiabetic medication |
1 |
|
antidiabetic medications |
1 |
|
antiepileptic |
1 |
|
antiepileptic drugs |
1 |
|
antiepileptic-drugs |
1 |
|
antiobesity drug |
1 |
|
antipsychotic agents |
1 |
|
antipsychotic agents - adverse effects |
1 |
|
antiretroviral |
1 |
|
appetite depressants - adverse effects - therapeutic use |
1 |
|
aripiprazole |
1 |
|
asia - epidemiology |
1 |
|
asthenia |
1 |
|
asthma - drug therapy |
1 |
|
asthma - drug therapy - psychology |
1 |
|
attempt |
1 |
|
attention deficit disorder with hyperactivity - drug therapy |
1 |
|
attention deficit disorder with hyperactivity - drug therapy - epidemiology - psychology |
1 |
|
attention deficit disorder with hyperactivity - drug therapy - mortality |
1 |
|
attention deficit disorder with hyperactivity - drug therapy - psychology |
1 |
|
attention deficit hyperactivity disorder (adhd) |
1 |
|
attitude to health |
1 |
|
atypical antipsychotic agent |
1 |
|
australia |
1 |
|
autism |
1 |
|
autistic spectrum disorder |
1 |
|
automutilation |
1 |
|
bariatric surgery |
1 |
|
behavior disorder |
1 |
|
behaviour therapy |
1 |
|
biomarker |
1 |
|
blood analysis |
1 |
|
body mass index |
1 |
|
body weight |
1 |
|
bone density conservation agents - administration & dosage |
1 |
|
breakthrough pain |
1 |
|
british national formulary |
1 |
|
cancer pain |
1 |
|
carbamazepine - therapeutic use |
1 |
|
cardiovascular diseases - chemically induced - diagnosis - mortality - prevention & control |
1 |
|
cardiovascular drugs |
1 |
|
case control |
1 |
|
case-crossover |
1 |
|
causal attribution |
1 |
|
cause of death |
1 |
|
central nervous system stimulants - administration & dosage - adverse effects |
1 |
|
central nervous system stimulants - administration & dosage - pharmacology |
1 |
|
central nervous system stimulants - adverse effects - therapeutic use |
1 |
|
checklist |
1 |
|
chemotherapy |
1 |
|
child & adolescent psychiatry |
1 |
|
child (under 12 years) |
1 |
|
child care |
1 |
|
child psychiatry |
1 |
|
child psychology |
1 |
|
child/adolescent/infant |
1 |
|
childhood disease |
1 |
|
childhood obesity |
1 |
|
children and adolescents |
1 |
|
chlorpromazine |
1 |
|
cholinergic antagonists - therapeutic use |
1 |
|
chronic epilepsy |
1 |
|
clinical coding |
1 |
|
clinical competence |
1 |
|
clinical databases |
1 |
|
clinical decision support systems |
1 |
|
clinical interventions |
1 |
|
clinical protocols |
1 |
|
clinical trials as topic |
1 |
|
clozapine |
1 |
|
co-morbidities |
1 |
|
co-morbidity |
1 |
|
cochrane library |
1 |
|
cognitive therapy |
1 |
|
combined modality therapy |
1 |
|
communication |
1 |
|
community pharmacy services - utilization |
1 |
|
comparative effectiveness |
1 |
|
complementary and alternative medicine |
1 |
|
compounding |
1 |
|
computer communication networks |
1 |
|
conduct disorder |
1 |
|
confidence interval |
1 |
|
confidence intervals |
1 |
|
congenital malformation |
1 |
|
constipation |
1 |
|
consultation |
1 |
|
consumer product safety |
1 |
|
continuity of patient care |
1 |
|
contraceptive agents - administration & dosage |
1 |
|
controlled clinical trial |
1 |
|
convulsion |
1 |
|
coronary heart disease |
1 |
|
coronavirus disease 2019 |
1 |
|
corticosterone - therapeutic use |
1 |
|
cost effectiveness analysis |
1 |
|
cost-effective |
1 |
|
cost-effectiveness |
1 |
|
cost-utility |
1 |
|
costs and cost analysis |
1 |
|
coughing |
1 |
|
counseling - methods |
1 |
|
covariate |
1 |
|
cross infection - prevention & control |
1 |
|
cross-sectional studies |
1 |
|
curriculum |
1 |
|
cyclobutanes - adverse effects - therapeutic use |
1 |
|
cyclobutanes - therapeutic use |
1 |
|
data analysis |
1 |
|
data base |
1 |
|
database studies |
1 |
|
database(s) |
1 |
|
databases |
1 |
|
databases, factual |
1 |
|
daytime somnolence |
1 |
|
death |
1 |
|
death, sudden - etiology |
1 |
|
defined daily dose |
1 |
|
definition |
1 |
|
depressive disorder - drug therapy |
1 |
|
dextroamphetamine - administration & dosage - pharmacology |
1 |
|
dextroamphetamine - adverse effects - therapeutic use |
1 |
|
dextroamphetamine - therapeutic use |
1 |
|
diabetes complications - epidemiology - prevention & control |
1 |
|
diabetes mellitus - blood - epidemiology - therapy |
1 |
|
diabetes mellitus - drug therapy |
1 |
|
diabetes mellitus, type 1 - drug therapy - epidemiology |
1 |
|
diabetes mellitus, type 2 - drug therapy - epidemiology |
1 |
|
diagnostic accuracy |
1 |
|
diclofenac |
1 |
|
diclofenac - adverse effects |
1 |
|
digestive system ulcer |
1 |
|
direct oral anticoagulant |
1 |
|
disease association |
1 |
|
disease classification |
1 |
|
disease progression |
1 |
|
dizziness |
1 |
|
dopamine uptake inhibitors - therapeutic use |
1 |
|
dosage forms |
1 |
|
dose |
1 |
|
dose calculation |
1 |
|
drug administration schedule |
1 |
|
drug effect |
1 |
|
drug eruptions - diagnosis |
1 |
|
drug induced disease |
1 |
|
drug interactions |
1 |
|
drug labeling |
1 |
|
drug monitoring |
1 |
|
drug prescriptions |
1 |
|
drug prescriptions - standards - statistics & numerical data |
1 |
|
drug prescriptions - statistics & numerical data |
1 |
|
drug prescriptions - statistics and numerical data |
1 |
|
drug rechallenge |
1 |
|
drug resistance |
1 |
|
drug surveillance program |
1 |
|
drug therapy |
1 |
|
drug therapy - adverse effects |
1 |
|
drug therapy - statistics & numerical data |
1 |
|
drug therapy, computer-assisted |
1 |
|
drug tolerance |
1 |
|
drug toxicity - chemically induced |
1 |
|
drug toxicity - epidemiology - physiopathology - prevention & control |
1 |
|
drug utilisation |
1 |
|
drug utilization - legislation & jurisprudence - trends |
1 |
|
drug utilization - statistics & numerical data |
1 |
|
drug utilization review |
1 |
|
drug-related problem |
1 |
|
drug-related problems |
1 |
|
drugs, investigational - therapeutic use |
1 |
|
dry powder inhalers |
1 |
|
ear disorders |
1 |
|
eating disorders |
1 |
|
education, continuing - standards |
1 |
|
education, medical, graduate - methods |
1 |
|
educational attainment |
1 |
|
educational measurement - methods |
1 |
|
efficiency, organizational |
1 |
|
electroconvulsive therapy |
1 |
|
electronic health record |
1 |
|
elimination diet |
1 |
|
embase |
1 |
|
emea |
1 |
|
emergencies |
1 |
|
emergency department |
1 |
|
end of life care |
1 |
|
epilepsy |
1 |
|
epilepsy - drug therapy |
1 |
|
epilepsy - drug therapy - mortality - physiopathology |
1 |
|
erratum |
1 |
|
error |
1 |
|
europe |
1 |
|
europe - epidemiology |
1 |
|
european |
1 |
|
evidence based medicine |
1 |
|
evidence-based medicine - statistics & numerical data |
1 |
|
extemporaneous preparations |
1 |
|
family |
1 |
|
family involvement |
1 |
|
family practice |
1 |
|
family practice - statistics & numerical data |
1 |
|
fatty acid |
1 |
|
feasibility studies |
1 |
|
fentanyl |
1 |
|
fine particle dose |
1 |
|
floxacillin - therapeutic use |
1 |
|
follow up |
1 |
|
follow-up studies |
1 |
|
food colours |
1 |
|
food supplements |
1 |
|
forms and records control - standards |
1 |
|
fructose - analogs & derivatives - therapeutic use |
1 |
|
gabapentin |
1 |
|
gamma-aminobutyric acid - adverse effects - analogs & derivatives |
1 |
|
general practice |
1 |
|
general practitioners |
1 |
|
gestational diabetes |
1 |
|
gfr |
1 |
|
global surveillance |
1 |
|
government |
1 |
|
gram-positive bacterial infections - drug therapy |
1 |
|
great britain - epidemiology |
1 |
|
growth |
1 |
|
guideline adherence - statistics & numerical data |
1 |
|
guidelines |
1 |
|
haloperidol |
1 |
|
health care access |
1 |
|
health care organization |
1 |
|
health care personnel |
1 |
|
health policy |
1 |
|
health program |
1 |
|
health promotion |
1 |
|
health service |
1 |
|
health services for the aged |
1 |
|
health services research |
1 |
|
hemoglobin a, glycosylated - metabolism |
1 |
|
hemorrhage |
1 |
|
hepatitis b, chronic - complications - economics - therapy |
1 |
|
herbal medicine |
1 |
|
high income country |
1 |
|
hks |
1 |
|
hodgson, c. |
1 |
|
home care |
1 |
|
hospital care |
1 |
|
hospital readmission |
1 |
|
hospital units |
1 |
|
hospitalised child |
1 |
|
hospitalised children |
1 |
|
hospitalized children |
1 |
|
hospitals, general |
1 |
|
hospitals, teaching |
1 |
|
hyperglycaemia |
1 |
|
hypoglycaemia |
1 |
|
hypoglycaemicevents |
1 |
|
hypoglycemic agents - therapeutic use |
1 |
|
ibuprofen - therapeutic use |
1 |
|
ideation |
1 |
|
information processing |
1 |
|
infusions, parenteral - adverse effects |
1 |
|
inpatient |
1 |
|
insulin - therapeutic use |
1 |
|
interdisciplinary communication |
1 |
|
international |
1 |
|
iohexol |
1 |
|
iontophoresis |
1 |
|
knowledge base |
1 |
|
lactones - adverse effects - therapeutic use |
1 |
|
lactones - therapeutic use |
1 |
|
lamotrigine |
1 |
|
legislation, drug |
1 |
|
legislation, drug - statistics & numerical data |
1 |
|
length of stay |
1 |
|
letter |
1 |
|
life style |
1 |
|
lifestyle intervention |
1 |
|
literature review |
1 |
|
london - epidemiology |
1 |
|
long-term methylphenidate treatment |
1 |
|
long-term treatment |
1 |
|
malaysia |
1 |
|
management |
1 |
|
manic depressive psychosis |
1 |
|
marketing authorisation |
1 |
|
mastoiditis |
1 |
|
medical education |
1 |
|
medical information |
1 |
|
medical order entry systems - organization & administration - standards - statistics & numerical data |
1 |
|
medical practice |
1 |
|
medical record |
1 |
|
medical research |
1 |
|
medical research council |
1 |
|
medical specialist |
1 |
|
medical staff, hospital - education |
1 |
|
medication |
1 |
|
medication adherence |
1 |
|
medication error |
1 |
|
medication errors - nursing - standards - statistics & numerical data |
1 |
|
medication errors - prevention & control - statistics & numerical data |
1 |
|
medication errors - statistics & numerical data |
1 |
|
medication history |
1 |
|
medication records |
1 |
|
medication systems, hospital |
1 |
|
medication systems, hospital - organization & administration - standards - statistics & numerical data |
1 |
|
medication systems, hospital - standards |
1 |
|
medication systems, hospital - standards - statistics & numerical data |
1 |
|
medication therapy management |
1 |
|
medicine management |
1 |
|
medicines and healthcare products regulatory agency |
1 |
|
medicines management |
1 |
|
metformin - therapeutic use |
1 |
|
methods |
1 |
|
methylphenidate - administration & dosage - pharmacology |
1 |
|
methylphenidate - adverse effects - therapeutic use |
1 |
|
methylphenidate - therapeutic use |
1 |
|
microbial |
1 |
|
middle income country |
1 |
|
minitablets |
1 |
|
monitoring |
1 |
|
monitoring, physiologic - methods - standards |
1 |
|
mood |
1 |
|
mrc framework |
1 |
|
multicentre study |
1 |
|
multiple medications |
1 |
|
national health programs |
1 |
|
national health service |
1 |
|
national service framework |
1 |
|
neurological pain |
1 |
|
neutropenia |
1 |
|
neutropenic sepsis |
1 |
|
new antiepileptic drugs |
1 |
|
non-invasive monitoring |
1 |
|
non-steroidal |
1 |
|
nonmem |
1 |
|
north america |
1 |
|
nursing staff, hospital - standards - statistics & numerical data |
1 |
|
obesity - drug therapy |
1 |
|
obesity - drug therapy - epidemiology |
1 |
|
obesity - psychology - therapy |
1 |
|
observation - methods |
1 |
|
off-label |
1 |
|
opioids |
1 |
|
oral anti-diabetics |
1 |
|
oral dosage form |
1 |
|
oral penicillin |
1 |
|
osteoporosis, postmenopausal - prevention & control - therapy |
1 |
|
otitis - drug therapy |
1 |
|
otitis media |
1 |
|
outcome and process assessment (health care) |
1 |
|
outcome assessment (health care) |
1 |
|
paediatric hospitals |
1 |
|
paediatric medicine |
1 |
|
paediatric palliative care |
1 |
|
pain |
1 |
|
pain - drug therapy |
1 |
|
pain management |
1 |
|
parent training |
1 |
|
parental attitude |
1 |
|
pathogenesis |
1 |
|
patient care |
1 |
|
patient education as topic - methods |
1 |
|
patient information leaflets |
1 |
|
patient involvement |
1 |
|
patient referral |
1 |
|
patient safety |
1 |
|
patient satisfaction |
1 |
|
patient satisfaction - statistics & numerical data |
1 |
|
patients |
1 |
|
pdiatrics |
1 |
|
pediatric asthma |
1 |
|
pediatrics - education |
1 |
|
pediatrics - methods |
1 |
|
peer review |
1 |
|
penicillin |
1 |
|
penicillin v - administration and dosage |
1 |
|
pharmaceutical care network europe |
1 |
|
pharmaceutical care network europe (pcne) |
1 |
|
pharmaceutical preparations - administration & dosage |
1 |
|
pharmaceutical preparations - adverse effects |
1 |
|
pharmaceutical preparations - supply & distribution |
1 |
|
pharmacist |
1 |
|
pharmacist intervention |
1 |
|
pharmacogenetics |
1 |
|
pharmacology |
1 |
|
pharmacy service, hospital - standards |
1 |
|
pharyngitis - drug therapy |
1 |
|
physician's practice patterns |
1 |
|
physician's practice patterns - legislation & jurisprudence - statistics & numerical data - trends |
1 |
|
physician's practice patterns - statistics & numerical data - trends |
1 |
|
physician's practice patterns - statistics and numerical data |
1 |
|
physician's practice patterns - trends |
1 |
|
plant |
1 |
|
pneumococcal conjugate vaccine |
1 |
|
pneumococcal infections |
1 |
|
pneumonia |
1 |
|
polycystic ovary syndrome |
1 |
|
polycystic ovary syndrome - drug therapy |
1 |
|
population pharmacokinetics |
1 |
|
postmenopausal women |
1 |
|
practice guidelines as topic |
1 |
|
predictors |
1 |
|
pregnant |
1 |
|
prescribing errors |
1 |
|
prescription |
1 |
|
prescription drugs |
1 |
|
preservatives |
1 |
|
preventers |
1 |
|
primary health care |
1 |
|
priority journal |
1 |
|
professional practice |
1 |
|
professional-family relations |
1 |
|
professional-patient relations |
1 |
|
prognosis |
1 |
|
prognostic factors |
1 |
|
propylamines - administration & dosage - adverse effects |
1 |
|
propylamines - administration & dosage - pharmacology |
1 |
|
propylamines - adverse effects - therapeutic use |
1 |
|
propylamines - therapeutic use |
1 |
|
prothrombin |
1 |
|
psychiatric diagnosis |
1 |
|
psychiatry and neurology |
1 |
|
psychometrics |
1 |
|
psychopharmacological prescribing |
1 |
|
psychotherapist |
1 |
|
psychotherapy |
1 |
|
psychotropic drugs - therapeutic use |
1 |
|
psychotropic medication |
1 |
|
qaly |
1 |
|
qualitative research |
1 |
|
randomised clinical trials |
1 |
|
randomised controlled trial |
1 |
|
randomized controlled trials as topic |
1 |
|
rash |
1 |
|
readability |
1 |
|
recurrence |
1 |
|
references (16) view in table layout |
1 |
|
references (20) view in table layout |
1 |
|
references (22) view in table layout |
1 |
|
references (26) view in table layout |
1 |
|
references (32) view in table layout |
1 |
|
references (4) view in table layout |
1 |
|
references (46) view in table layout |
1 |
|
references (48) view in table layout |
1 |
|
relative lung bioavailability |
1 |
|
relievers |
1 |
|
reproducibility of results |
1 |
|
research |
1 |
|
research and development |
1 |
|
respiratory tract infections - diagnosis - drug therapy |
1 |
|
retention |
1 |
|
retention rates |
1 |
|
retrospective study |
1 |
|
review literature as topic |
1 |
|
risk |
1 |
|
risk assessment |
1 |
|
risk benefit analysis |
1 |
|
risk reduction |
1 |
|
risperidone |
1 |
|
safety management - methods |
1 |
|
saudi arabia |
1 |
|
school health services - organization & administration - standards |
1 |
|
school of pharmacy, university of bradford.,
© medline® is the source for the citation and abstract of this record. |
1 |
|
secondary care |
1 |
|
seizure free-retention rate |
1 |
|
short survey |
1 |
|
side effect |
1 |
|
singapore |
1 |
|
skin rash |
1 |
|
society |
1 |
|
sore throat |
1 |
|
south america |
1 |
|
species index: bacteria (microorganisms) |
1 |
|
staphylococcal skin infections - complications - drug therapy - epidemiology - microbiology |
1 |
|
staphylococcus aureus - isolation & purification |
1 |
|
status epilepticus - etiology - mortality |
1 |
|
stimulant |
1 |
|
student |
1 |
|
substance withdrawal syndrome - physiopathology |
1 |
|
substance-related disorders - etiology - prevention & control |
1 |
|
sudden-death |
1 |
|
suicidal ideation |
1 |
|
suicide - prevention & control - psychology |
1 |
|
suicide - statistics & numerical data |
1 |
|
suicide, attempted - prevention & control - psychology |
1 |
|
supercritical fluids |
1 |
|
survival analysis |
1 |
|
suspension |
1 |
|
symptom management |
1 |
|
symptomatology |
1 |
|
tacrolimus |
1 |
|
teaching - methods |
1 |
|
terminal care |
1 |
|
thioridazine |
1 |
|
time factors |
1 |
|
tonsillitis - drug therapy |
1 |
|
topiramate |
1 |
|
training |
1 |
|
transdermal sampling |
1 |
|
treatment trials |
1 |
|
trend |
1 |
|
triazines - administration & dosage - adverse effects |
1 |
|
triazines - therapeutic use |
1 |
|
type 1 diabetes |
1 |
|
uk |
1 |
|
university hospital |
1 |
|
unlicensed |
1 |
|
urinary salbutamol |
1 |
|
us food and drug administration |
1 |
|
validation |
1 |
|
valproic acid - therapeutic use |
1 |
|
vehicles |
1 |
|
vision disorders - chemically induced |
1 |
|
visual fields |
1 |
|
waist circumference - drug effects |
1 |
|
ward pharmacy |
1 |
|
warfarin reversal |
1 |
|
weight gain |
1 |
|
withholding treatment |
1 |
|
withholding treatment - trends |
1 |
|
women's health |
1 |
|
young adult |
1 |
|
young adults |
1 |
